Interventional cardiology -: Peroxisome proliferator-activated receptor γ agonists for the Prevention of Adverse events following percutaneous coronary Revascularization -: results of the PPAR Study

Background Patients with metabolic syndrome are at increased risk for cardiovascular complications. We sought to determine whether peroxisome proliferator-activated receptor gamma agonists had any beneficial effect on patients with metabolic syndrome undergoing percutaneous coronary intervention (PCI). Methods A total of 200 patients with metabolic syndrome undergoing PCI were randomized to rosiglifazone or placebo and followed for 1 year. Carotid intima-medial thickness (CIMT), inflammatory markers, lipid levels, brain natriuretic peptide, and clinical events were measured at baseline, 6 months, and 12 months. Results There was no significant difference in CUT between the 2 groups. There was no difference in the 12-month composite end point of death, myocardial infarction (MI), stroke, or any recurrent ischemia (3 1.4% vs 30.2%, P =.99). The rate of death, Ml, or stroke at 12 months was numerically lower in the rosiglitazone group (11.9% vs 6.4%, P =.19). There was a trend toward a greater decrease over time in high-sensitivity C-reactive protein values compared with baseline in the group randomized to rosiglitazone versus placebo both at 6 months (-35.4% vs - 15.8%, P =.059) and 12 months (-40.0%. vs -20.9%, P =.089) and higher change in high-density lipoprotein (+ 15.5% vs +4. 1 %, P =.05) and lower triglycerides (- 13.9% vs + 14.9%, P =.004) in the rosiglitazone arm. There was a trend toward less new onset diabetes in the rosiglitazone group (0% vs 3.3%, P =.08 1) and no episodes of symptomatic hypoglycernia. There was no excess of new onset of clinical heart failure in the rosiglitozone group, nor was there a significant change in brain natriuretic pepticle levels. Conclusions Patients with metabolic syndrome presenting for PCI are at increased risk for subsequent cardiovascular events. Rosiglitazone for 12 months did not appear to affect CUT in this population, although it did have beneficial effects on high-sensitivity C-reactive protein, high-density lipoprotein, and triglycerides. Further study of peroxisome proliferator-activated receptor agonism in patients with metabolic syndrome undergoing PCI may be warranted.